Show simple item record

dc.contributor.authorWassenberg, Tessaen_US
dc.contributor.authorMolero-Luis, Martaen_US
dc.contributor.authorJeltsch, Kathrinen_US
dc.contributor.authorHoffmann, Georg F.en_US
dc.contributor.authorAssmann, Birgiten_US
dc.contributor.authorBlau, Nenaden_US
dc.contributor.authorGarcia-Cazorla, Angelesen_US
dc.contributor.authorArtuch, Rafaelen_US
dc.contributor.authorPons, Roseren_US
dc.contributor.authorPearson, Toni S.en_US
dc.contributor.authorLeuzzi, Vincencoen_US
dc.contributor.authorMastrangelo, Marioen_US
dc.contributor.authorPearl, Phillip L.en_US
dc.contributor.authorLee, Wang Tsoen_US
dc.contributor.authorKurian, Manju A.en_US
dc.contributor.authorHeales, Simonen_US
dc.contributor.authorFlint, Lisaen_US
dc.contributor.authorVerbeek, Marcelen_US
dc.contributor.authorWillemsen, Michèlen_US
dc.contributor.authorOpladen, Thomasen_US
dc.date.accessioned2017-02-18T01:58:07Z
dc.date.issued2017en_US
dc.identifier.citationWassenberg, T., M. Molero-Luis, K. Jeltsch, G. F. Hoffmann, B. Assmann, N. Blau, A. Garcia-Cazorla, et al. 2017. “Consensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiency.” Orphanet Journal of Rare Diseases 12 (1): 12. doi:10.1186/s13023-016-0522-z. http://dx.doi.org/10.1186/s13023-016-0522-z.en
dc.identifier.issn1750-1172en
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:30370959
dc.description.abstractAromatic L-amino acid decarboxylase deficiency (AADCD) is a rare, autosomal recessive neurometabolic disorder that leads to a severe combined deficiency of serotonin, dopamine, norepinephrine and epinephrine. Onset is early in life, and key clinical symptoms are hypotonia, movement disorders (oculogyric crisis, dystonia, and hypokinesia), developmental delay, and autonomic symptoms. In this consensus guideline, representatives of the International Working Group on Neurotransmitter Related Disorders (iNTD) and patient representatives evaluated all available evidence for diagnosis and treatment of AADCD and made recommendations using SIGN and GRADE methodology. In the face of limited definitive evidence, we constructed practical recommendations on clinical diagnosis, laboratory diagnosis, imaging and electroencephalograpy, medical treatments and non-medical treatments. Furthermore, we identified topics for further research. We believe this guideline will improve the care for AADCD patients around the world whilst promoting general awareness of this rare disease. Electronic supplementary material The online version of this article (doi:10.1186/s13023-016-0522-z) contains supplementary material, which is available to authorized users.en
dc.language.isoen_USen
dc.publisherBioMed Centralen
dc.relation.isversionofdoi:10.1186/s13023-016-0522-zen
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/pdf/en
dash.licenseLAAen_US
dc.subjectAromatic l-amino acid decarboxylase deficiencyen
dc.subjectAADC deficiencyen
dc.subjectNeurotransmitteren
dc.subjectDopamineen
dc.subjectSerotoninen
dc.subjectGuidelineen
dc.subjectInfantile dystonia-parkinsonismen
dc.subjectSIGNen
dc.subjectGRADEen
dc.titleConsensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiencyen
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalOrphanet Journal of Rare Diseasesen
dash.depositing.authorPearl, Phillip L.en_US
dc.date.available2017-02-18T01:58:07Z
dc.identifier.doi10.1186/s13023-016-0522-z*
dash.authorsorderedfalse
dash.contributor.affiliatedPearl, Phillip


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record